Summary
The ‘Workshop on Growth Factors’ which took place at the Lugano Lymphoma Conference on June 8, 1990, included a presentation by Michael Sporn on the concept that loss of inhibitory control mechanisms may be important in the development and growth of human cancer. Examples illustrating this were taken from current experimental biology research into transforming growth factor β (TGF-β) interactions. Brian Durie presented recent data on the biology of interleukin-6 (IL-6) and its putative role in plasma cell diseases. These studies have culminated in the first clinical study of the role of an antibody to a growth factor as therapy for a human cancer (anti-IL-6 antibody as therapy for patients with myeloma). Derek Crowther presented data concerning the current clinical role of the haematopoietic growth factors in patients undergoing chemotherapy for cancer. Recent clinical research has established the role of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in improving the safety of high-dose or accelerated chemotherapy, and their use is associated with enhanced neutrophil recovery following ablative therapy and bone marrow rescue. This session was followed by the presentation of three papers concerning the use of G-CSF and GM-CSF in association with chemotherapy for patients with malignant lymphoma.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kishimoto T. The Biology of Interleukin-6. Blood 1989; 74: 1, 1–10.
Kawano M, Hirano T, Matsuda T, Taga T, Horil Y, Iwato K, Asoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83.
Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochemical J 1990; 265: 621.
Lichtenstein A, Berenson J, Norman D, Chang MP, Cattle A. Production of Cytokines by Bone Marrow Cells Obtained from Patients with Multiple Myeloma. Blood 1989; 74: 1266–73.
Zhang XG, Klein B, Bataille R. Interleukin-6 is a Potent Myeloma-Cell Growth Factor in Patients with Aggressive Multiple Myeloma. Blood 1989; 74: 11–3.
Durie BGM, Vela EE, Frutiger Y. Macrophages as an Important Source of Paracrine IL-6 in Myeloma Bone Marrow. In: Proceedings of Mechanisms in B Cell Neoplasia 1990. ( In press )
Bataille R, Jourdan M, Zhang XG, Klein B. Serum Levels of Interleukin-6, A Potent Myeloma Cell Growth Factor, As A Reflect of Disease Severity in Plasma Cell Dyscrasias. J Clin Invest (In Press).
Freeman GJ, Freedman AS, Rabinowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM. Interleukin-6 Gene Expression in Normal and Neoplastic B cells. J Clin Invest 1989; 83: 1512–8.
Jourdan M, Bataille R, Sequin J, Zhang XG, Chaptal PA, Klein B. Constitutive Production of Interleukin and Immunologic Features in Cardiac Myxomas. Arthritis & Rheumatism 1990; 33: 1–5.
Tohyama N, Karasuyama H, Tada T. Growth Autonomy and Tumorigenicity of Interleukin 6-Dependent B Cells Transfected with Interleukin 6 cDNA. J Exp Med 1990; 171: 389–400.
Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T, Kishimoto T. Interleukin-6 Triggers the Association of Its Receptor with a Possible Signal Transducer, gp130. Cell 1989 58: 573–81.
Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza M, Alton NK, Testa NG, Dexter TM. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987; 56: 809–13.
Gurney H, Crowther D. Hemopoietic growth factors: their clinical role (Ed: J. R. Prous). Drugs of the Future 1990; 15: No. 6, 581–595.
Crawford J, Ozer H, Johnson. The G-CSF study group. Granulocyte colony stimulating factor: prevention of chemotherapy induced neutropneia in patients with small cell lung cancer. A randomised bould eblind placebo controlled trial. Proc Amer Soc Clin Oncol 1990; 9: 229.
Ganser A, Lindemann A, Seipelt G, Ottmann OG, Herrmann F, Schulz G, Mertelsman R, Hoelzer D. Effect of recombinant human interleukin-3 (rhIL-3) in patients with bone marrow failure — A phase I/II trial. Blood 1989; 74 (7), Suppl. 1, 50a.
Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Allessandro P, Bonadonna G. Granulocyte-macrophage colony stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580.
Gurney H, Crowther D. Hemopoietic growth factors: their clinical role. Drugs of the Future 1990; 15: No. 6, (In press).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Crowther, D., Sporn, M.B., Roberts, A.B., Durie, B.G.M. (1991). Workshop on growth factors. In: Ultmann, J.E., Samuels, B.L. (eds) Annals of Oncology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-7305-4_33
Download citation
DOI: https://doi.org/10.1007/978-1-4899-7305-4_33
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-7294-1
Online ISBN: 978-1-4899-7305-4
eBook Packages: Springer Book Archive